Seres Therapeutics (MCRB) Accounts Payables: 2015-2025
Historic Accounts Payables for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $1.7 million.
- Seres Therapeutics' Accounts Payables fell 79.68% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 79.68%. This contributed to the annual value of $4.1 million for FY2024, which is 12.03% up from last year.
- Per Seres Therapeutics' latest filing, its Accounts Payables stood at $1.7 million for Q3 2025, which was down 23.77% from $2.2 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Accounts Payables peaked at $17.4 million during Q4 2022, and registered a low of $1.7 million during Q3 2025.
- Over the past 3 years, Seres Therapeutics' median Accounts Payables value was $4.8 million (recorded in 2024), while the average stood at $6.0 million.
- Per our database at Business Quant, Seres Therapeutics' Accounts Payables soared by 241.84% in 2021 and then crashed by 79.68% in 2025.
- Quarterly analysis of 5 years shows Seres Therapeutics' Accounts Payables stood at $13.7 million in 2021, then rose by 26.97% to $17.4 million in 2022, then plummeted by 79.12% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024, then crashed by 79.68% to $1.7 million in 2025.
- Its Accounts Payables stands at $1.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.